Study of the possible protective effects of montelukast in rotenone induced-parkinson{u2019}s disease model in rats /
Riham Mahmoud Mansour
Study of the possible protective effects of montelukast in rotenone induced-parkinsons disease model in rats / دراسة التأثيرات الوقائية المحتملة لمونتيلوكاست في نموذج مرض باركينسون في الجرذان بفعل روتينون Riham Mahmoud Mansour ; Supervised Nesrine Salah Eldin Elsayed , Maha Ali Eissa Ahmed , Ayman Elsayed Mohamed Elsahar - Cairo : Riham Mahmoud Mansour , 2019 - 138 P. : charts , facsimiles ; 25cm
Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology
Montelukast (MK), a cysteinyl leukotriene receptor (CysLT1R) antagonist, latterly exhibited a remarkable neuroprotective activity in various neurodegenerative disorders. However, its neuroprotective outcome versus Parkinsons disease (PD) remains vague. The current study investigated the neuroprotective effects of montelukast in rotenone-induced Parkinsons disease (PD) rat model. Rotenone was administered as 11 subcutaneous injections at a dose of 1.5 mg/kg every other day. Montelukast (10 mg/kg) was given intraperitoneally one hour before rotenone injections. Administration of both drugs was continued for 21 days. Then, all rats were screened for motor behavioral impairment using the open field and rotarod tests. Thereafter, rats were sacrificed, decapitated and brains were rapidly dissected out for separation of both striata. Striatal contents of oxidative stress, inflammatory and apoptotic biomarkers were determined. Besides, cysteinyl leukotrienes 1 receptor (CysLT1R) and p38 mitogen-activated protein kinase (p38 MAPK) expressions were estimated. In addition, histopathology, tyrosine hydroxylase (TH) and microglia activity were evaluated in the striata of rats
Montelukast Parkinsons disease Rotenone
Study of the possible protective effects of montelukast in rotenone induced-parkinsons disease model in rats / دراسة التأثيرات الوقائية المحتملة لمونتيلوكاست في نموذج مرض باركينسون في الجرذان بفعل روتينون Riham Mahmoud Mansour ; Supervised Nesrine Salah Eldin Elsayed , Maha Ali Eissa Ahmed , Ayman Elsayed Mohamed Elsahar - Cairo : Riham Mahmoud Mansour , 2019 - 138 P. : charts , facsimiles ; 25cm
Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology
Montelukast (MK), a cysteinyl leukotriene receptor (CysLT1R) antagonist, latterly exhibited a remarkable neuroprotective activity in various neurodegenerative disorders. However, its neuroprotective outcome versus Parkinsons disease (PD) remains vague. The current study investigated the neuroprotective effects of montelukast in rotenone-induced Parkinsons disease (PD) rat model. Rotenone was administered as 11 subcutaneous injections at a dose of 1.5 mg/kg every other day. Montelukast (10 mg/kg) was given intraperitoneally one hour before rotenone injections. Administration of both drugs was continued for 21 days. Then, all rats were screened for motor behavioral impairment using the open field and rotarod tests. Thereafter, rats were sacrificed, decapitated and brains were rapidly dissected out for separation of both striata. Striatal contents of oxidative stress, inflammatory and apoptotic biomarkers were determined. Besides, cysteinyl leukotrienes 1 receptor (CysLT1R) and p38 mitogen-activated protein kinase (p38 MAPK) expressions were estimated. In addition, histopathology, tyrosine hydroxylase (TH) and microglia activity were evaluated in the striata of rats
Montelukast Parkinsons disease Rotenone